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Summary
 
Hepatocellular carcinoma (HCC) is a common complication of chronic hepatitis B virus
(HBV) infection. The pathogenetic mechanisms potentially responsible for HCC during
chronic HBV infection are not well defined. This study demonstrates that chronic immune-
mediated liver cell injury triggers the development of HCC in the absence of viral transactiva-
tion, insertional mutagenesis, and genotoxic chemicals. These results strongly suggest that the
immune response to HBV is both necessary and sufficient to cause liver cancer during chronic
HBV infection, and that all other procarcinogenic events associated with HCC are probably
dependent on this process.
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A
 
ntiviral T cells are believed to play a major role in the
control of hepatitis B virus (HBV)
 
1
 
 infection. In sup-
port of this notion, the T cell response to HBV has been
shown to be vigorous, polyclonal, and multispecific in pa-
tients with acute hepatitis who ultimately clear the virus,
whereas it is relatively weak and narrowly focused in pa-
tients with chronic hepatitis, except during acute exacerba-
tions of chronic disease (1, 2). The relative inefficiency of
the T cell response in persistently infected patients is
thought to cause chronic hepatitis by destroying some but
not all of the infected cells, setting up a cycle of liver cell
destruction and regeneration in the context of continuous
intrahepatic inflammation that often terminates in hepato-
cellular carcinoma (HCC; references 3–7).
The mechanisms responsible for malignant transforma-
tion in chronic HBV infection are not well defined, and
both viral and host factors have been implicated in the process.
On the one hand, all cases of HCC occur after many years
of chronic hepatitis, which could theoretically provide the
mitogenic and mutagenic environment to precipitate ran-
dom genetic and chromosomal damage and lead to the de-
velopment of HCC. On the other hand, most tumors con-
tain clonally integrated HBV DNA and microdeletions in
the flanking cellular DNA, which could theoretically de-
regulate cellular growth control mechanisms (8). Further-
more, the HBV X gene product has been shown to trans-
activate cellular genes associated with cellular growth
control (9–11) and inhibit p53 gene function in vitro (12),
suggesting that deregulated X gene expression from inte-
grated fragments of subviral DNA could play a role in
hepatocarcinogenesis (13). Similarly, COOH-terminally trun-
cated viral envelope proteins expressed from integrated subvi-
ral DNA may have transactivating activity (14, 15) and
could potentially contribute to carcinogenesis in chronic HBV
infection. However, like many retroviruses, HBV integra-
tion does not occur in resting hepatocytes; therefore, if
HBV integration plays a role in hepatocarcinogenesis, ante-
cedent events must occur that trigger hepatocellular turn-
over.
In an effort to clarify the carcinogenic potential of
chronic hepatitis, we showed previously that transgenic
mice that produce hepatotoxic quantities of the HBV large
envelope polypeptide (16–19) display hepatocellular injury,
regenerative hyperplasia, chronic inflammation, Kupffer
cell hyperplasia, oxygen radical production, glutathione de-
pletion, oxidative DNA damage, transcriptional deregula-
tion, and aneuploidy that inexorably progress to HCC (18–
23). Although those studies demonstrated that HBV can
cause HCC in the absence of insertional mutagenesis, X
gene expression, or genotoxic chemicals, they did not
prove that chronic immune-mediated hepatitis was a pro-
carcinogenic stimulus in itself. Therefore, this study was
undertaken to determine whether HCC can be triggered
by a chronic, virus-specific immune response in HBV
transgenic mice.
 
1
 
Abbreviations used in this paper:
 
 anti-HBs Ab, antibody to HBsAg; BMR,
bone marrow reconstitution; HBsAg, hepatitis B surface antigen; HBs-
vac, recombinant vaccinia virus that expresses HBsAg; HBV, hepatitis B
virus; HCC, hepatocellular carcinoma; sALT, serum alanine aminotrans-
ferase.
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Materials and Methods
 
HBV Transgenic Mice.
 
Production and characterization of
transgenic mouse lineage 107-5D (official designation Tg[Alb-
1,HBV]Bri66; inbred B10D2, H-2
 
d
 
) have been described previ-
ously (17). Lineage 107-5D contains the entire HBV envelope
coding region (subtype ayw) under the constitutive transcrip-
tional control of the mouse albumin promoter (17). These mice
express the HBV small, middle, and large envelope proteins in
their hepatocytes (17, 18), are immunologically tolerant to hepa-
titis B surface antigen (HBsAg) at the T cell level (24), and display
no evidence of liver disease during their lifetime, although they
do develop “ground glass” hepatocytes due to overexpression of
the large envelope protein (17). There is no X-RNA or X-pro-
tein expression detectable in the livers of these animals (our un-
published observations). Importantly, the mice develop a severe
MHC class I–restricted necroinflammatory liver disease after the
adoptive transfer of HBsAg-specific CTLs (17, 25, 26).
 
Thymectomy, Irradiation, Bone Marrow Reconstitution, and Spleen
Cell Transfer.
 
18 8–10-wk-old male transgenic mice were
thymectomized as described (27). 7 d later, the mice were irradi-
ated (900 cGy) from a 
 
137
 
Cs source (Gammacell 40 irradiator;
Atomic Energy of Canada, Ltd., Ottawa, Canada), then divided
into two groups for bone marrow reconstitution (BMR) with
nontransgenic or transgenic donor bone marrow that had been
depleted of T cells by complement fixation using anti-Thy1.2 Ab
(PharMingen, San Diego, CA). Group 1 recipients (nine mice),
the primary experimental animals in this study, were reconsti-
tuted by the intravenous injection of 10
 
7
 
 bone marrow cells col-
lected from the femurs and tibias of syngeneic nontransgenic
B10D2 (H-2
 
d
 
) mice. To control for the potential hepatocarcino-
genic effect of irradiation, group 2 recipients (nine mice) were re-
constituted with bone marrow cells derived from their immuno-
logically tolerant inbred transgenic littermates. 1 wk after bone
marrow reconstitution, the group 1 animals received 2 
 
3
 
 10
 
8
 
splenocytes from nontransgenic B10D2 (H-2
 
d
 
) mice that had
been infected intraperitoneally 3 wk earlier with a recombinant
vaccinia virus (HBs-vac) which expresses HBsAg, as described
(25). At the same time, the group 2 animals received the same
number of splenocytes from saline-injected, immunologically tol-
erant transgenic littermates. A third group of 10 transgenic mice
(group 3) remained unmanipulated for the entire experiment for
baseline comparison.
 
Disease Model.
 
All three groups of mice were analyzed for ev-
idence of HBsAg-specific immunity and liver disease before and
after BMR and after spleen cell transfer. Serum levels of HBsAg
and anti-HBs were assessed by radioimmunoassay (AUSRIA II;
Abbott Laboratories, North Chicago, IL) and enzyme-linked im-
munoassay (AUSAB EIA; Abbott Laboratories), respectively, as
described (28). Hepatocellular injury was monitored biochemi-
cally as serum alanine aminotransferase (sALT) activity (19). Re-
sults were expressed as mean units per liter 
 
6
 
 SEM of sALT ac-
tivity, and differences between experimental and control groups
were assessed for statistical significance by Student’s 
 
t
 
 test. Tumor
development was assessed by abdominal palpation and confirmed
by autopsy, at which time the number of tumors visible at the
surface of each liver was counted. Livers were then sectioned and
examined for evidence of additional tumors not visible on the
surface, and the diameter of each tumor was measured with a mil-
limeter rule. Mice were killed by cervical dislocation. Tissue sam-
ples were fixed in 10% zinc-buffered formalin (Anatech Ltd., Bat-
tle Creek, MI), embedded in paraffin, sectioned (3 
 
m
 
m), and
stained with hematoxylin and eosin as described (19). The intra-
hepatic distribution of HBsAg was assessed by the indirect immu-
noperoxidase method using 3-amino-9-ethyl carbazole (AEC;
Shandon, Inc., Pittsburgh, PA) as a coloring substrate, as de-
scribed previously (18). Liver tissue was also snap-frozen in liquid
nitrogen and stored at 
 
2
 
80
 
8
 
C for molecular analysis. 10 
 
m
 
g of to-
tal RNA was extracted from nontumorous liver tissue of repre-
sentative mice from each group and subjected to RNase protec-
tion analysis to monitor the expression of CD3
 
g
 
, CD4, CD8
 
a
 
,
F480, and a panel of inflammatory cytokines as described previ-
ously (28).
 
CTL Analysis.
 
Donor and recipient spleen cells were stimu-
lated in vitro every 7 d with irradiated P815 cells that stably ex-
press the HBV envelope proteins (P815preS1 cells), as described
(29). 2 wk later, the cytolytic activity of the resultant T cell lines
was assessed in a standard 4-h cytotoxicity assay with 
 
51
 
Cr-labeled
P815, P815preS1 target cells, and P815 cells that had been pulsed
either with different concentrations of a synthetic peptide repre-
senting residues 28–39 of HBsAg or with media, as described
(25). In selected experiments, the HBsAg-specific cytolytic activ-
ity against P815 and P815-S target cells (E/T ratio 50:1) was
tested in the presence of a rat mAb specific for mouse CD4 or
CD8 (1 
 
m
 
g/ml; PharMingen), or a control Ab (purified rat IgG, 1
 
m
 
g/ml; PharMingen). All experiments were performed in dupli-
cate. Percent specific
 
 51
 
Cr release was derived as follows: (experi-
mental cpm 
 
2
 
 spontaneous cpm)/(total cpm 
 
2
 
 spontaneous
cpm) 
 
3
 
 100. Spontaneous release was always 
 
,
 
20% of the total.
 
Results
 
Anti-HBs Abs and Transaminase Profiles after Adoptive
Transfer.
 
Two groups of 8–10-wk-old male transgenic
mice were thymectomized (27), irradiated, and reconsti-
tuted with either syngeneic nontransgenic (group 1) or
transgenic (group 2) T cell–depleted donor bone marrow.
1 wk after BMR, group 1 recipients received 2 
 
3
 
 10
 
8
 
 sple-
nocytes from syngeneic nontransgenic mice that had been
primed with HBs-vac, as described (25). Simultaneously,
group 2 animals received the same number of splenocytes
from saline-injected, immunologically tolerant transgenic
littermates, thereby serving as radiation controls. A third
group of 10 transgenic mice (group 3) remained unmanip-
ulated for the entire experiment.
In keeping with our previous reports (24–26), the HBs-
vac–immunized nontransgenic donors displayed high titers
of serum anti-HBs Abs and HBsAg-specific CTLs in their
spleens (not shown). In contrast, the transgenic donors
were anti-HBs–negative, and their splenocytes displayed
no HBsAg-specific CTL activity, confirming that this lin-
eage is immunologically tolerant to HBsAg. Consistent
with the transfer of HBsAg-specific B cells, HBsAg disap-
peared from the serum of group 1 mice within 3 d after
adoptive transfer (Fig. 1 
 
A
 
), concomitant with the appear-
ance of anti-HBs (not shown). Furthermore, consistent
with the transfer of HBsAg-specific CTLs, sALT activity
increased from preinjection levels of 20–40 U/liter to
 
z
 
4,000 U/liter in group 1 recipients within 7 d after adop-
tive transfer, and fell progressively thereafter (Fig. 1 
 
B
 
). Im-
portantly, sALT activity never returned to baseline in these
animals, remaining at least two to three times above normal 
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(except for the 270-d time point) and rising by 17 mo after
BMR and spleen cell transfer (Fig. 1 
 
B
 
, and Table 1), at
which time the animals were killed. We do not think the
decrease in sALT activity in group 1 at 270 d reflects tem-
porary resolution of disease, since the mice showed signifi-
cant histological evidence of chronic hepatitis before (at
240 d) and after (at 510 d) this time point (Fig. 2). The rise
in sALT in groups 1 and 2 at 510 d reflects a combination
of tumor necrosis and the destruction of normal hepato-
cytes by the expanding tumors. In contrast to these obser-
vations, serum HBsAg levels did not fall in group 2 or
group 3 mice (Fig. 1 
 
A
 
), in keeping with the absence of
anti-HBs in their serum (not shown). Similarly, sALT ac-
tivity remained in the normal range in group 2 and group 3
animals throughout most of the study, although they did
rise late in the experiment in a few of the group 2 radiation
controls (Fig. 1 
 
B
 
, and Table 1).
 
Chronic Hepatitis and HCC. 
 
The differential sALT ac-
tivity in the animals was reflected in the gross and histolog-
ical appearance of their livers at various times after BMR
and spleen cell transfer as illustrated in Fig. 2. Group 1 ani-
mals analyzed 3 wk after spleen cell transfer (
 
top left
 
) re-
vealed a subacute inflammatory liver disease of variable se-
verity characterized by a diffuse lymphomononuclear and
polymorphonuclear inflammatory infiltrate in the paren-
chyma and portal areas, focal hepatocellular necrosis and
dropout (
 
arrows
 
), and disorganization of the hepatic lobular
architecture. 3 mo later (
 
top right
 
), the mice displayed mul-
tiple portal and intralobular inflammatory infiltrates and
moderate lobular disarray
 
 
 
indicative of chronic hepatitis.
By 8 mo of age (
 
middle
 
), the liver disease in these animals
was more severe.
 
 
 
The left panel illustrates marked lobular
disarray, small focal inflammatory infiltrates associated with
degenerating hepatocytes, acidophil bodies (
 
asterisk
 
), and
marked variation in the size and shape of the hepatocytes,
some of which display nuclear pseudoinclusions (
 
arrows
 
).
The other 8-mo specimen (
 
right
 
) illustrates a portal inflam-
matory infiltrate with piecemeal necrosis of the limiting
plate, and a glycogen-rich altered hepatic focus (
 
arrowheads
 
)
containing numerous hepatocytes with prominent nucleoli
(features traditionally associated with preneoplastic foci).
Eventually, when the animals were killed 17 mo later (
 
bot-
tom
 
), they all displayed multiple liver tumors, most of
which were 
 
.
 
10 mm in diameter (Table 1). The tumors in
all but one of these animals displayed the classical histologi-
cal features of trabecular HCC (Fig. 2, 
 
bottom
 
) characterized
by trabecular cords composed of several layers of well-dif-
ferentiated neoplastic hepatocytes that contained abundant
granular eosinophilic cytoplasm and prominent nucleoli
covered by a thin endothelial lining and were arranged in
nests and cords several cells thick that displayed increased
mitotic activity (not shown), compressed the adjacent he-
patic parenchyma, and displayed areas of hemorrhage and
necrosis (not shown).
In contrast to these findings, the radiation control mice
in group 2 displayed much less severe necroinflammatory
changes in their livers at the time of autopsy, consistent
with their lower sALT levels. Interestingly, two of the nine
mice in this group displayed solitary liver tumors up to 10
mm in diameter, one of which was classified histologically
as a well-differentiated, trabecular HCC, whereas the other
was a benign adenoma characterized by sheets of normal-
appearing, glycogen-rich hepatocytes without portal tracts
or central veins
 
 
 
(Table 1). Not surprisingly, the livers of
group 3 mice were grossly and histologically normal, ex-
cept for the presence of HBsAg
 
1
 
 ground glass hepatocytes
characteristic of this lineage (not shown). The livers of all
of the animals in this study contained HBsAg
 
1
 
 hepatocytes
at the time of autopsy; however, the frequency of such
hepatocytes was much lower in group 1 animals (0.01–
15%) than in groups 2 and 3 (30–60%), presumably reflect-
Figure 1. Kinetics of serum HBsAg (A) and ALT (B) in HBV trans-
genic mice. Group 1 mice (open circles; n 5 9) were thymectomized, le-
thally irradiated, and reconstituted with bone marrow and spleen cells
from syngeneic nontransgenic donors that had been previously immu-
nized with recombinant vaccinia virus HBs-vac. Similarly treated group 2
transgenic control animals (filled circles; n 5 9) were reconstituted with
bone marrow and spleen cells from immunologically tolerant transgenic
donors that had been injected with saline. All results were compared with
group 3 unmanipulated age- and sex-matched transgenic mice (open trian-
gles; n 5 10). Adoptive transfer of splenocytes was performed on day 0.
Results were expressed as mean units per liter 6 SEM of sALT activity,
and differences between experimental and control groups were assessed
for statistical significance by Student’s t test. 
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Figure 2. Histopathological features of prolonged chronic immune-mediated hepatitis in HBV transgenic mice (group 1). Mice were killed by cervical
dislocation at the indicated time points. The 3-wk specimen illustrates portal and parenchymal inflammatory infiltrates with focal hepatocellular dropout
(arrows) and hepatocellular apoptosis (asterisk). The 3-mo specimen displays lymphocytic portal infiltrates and moderate disarray of the lobular architecture.
In addition, several lobular inflammatory foci were observed at this time point (not shown). The 8-mo specimen (left) illustrates marked lobular disarray,
small focal lobular inflammatory infiltrates associated with degenerating hepatocytes, acidophil bodies (asterisk), and marked variation in the size and shape
of many hepatocytes, some of which display nuclear pseudoinclusions (arrows). The other 8-mo specimen (right) illustrates a portal inflammatory infiltrate
(at the left of the photo) with piecemeal necrosis of the limiting plate, and a glycogen-rich altered hepatic focus (arrowheads) containing numerous hepa-
tocytes with prominent nucleoli (features traditionally associated with preneoplastic foci). Both of the 17-mo specimens, taken from large (.15 mm di-
ameter) tumors from different animals, illustrate the classical histological features of trabecular HCC consisting of relatively well-differentiated hepatocytes
with granular eosinophilic cytoplasm, arranged in nests and cords several cells thick that display increased mitotic activity, compress the adjacent hepatic
parenchyma, and display areas of hemorrhage and necrosis (not shown). Hematoxylin and eosin; original magnification: 3200. 
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ing the destruction of antigen-positive hepatocytes by the
immune response and, perhaps, the downregulation of an-
tigen expression by inflammatory cytokines, as described
previously (28, 30).
 
Intrahepatic T Cell and Cytokine Profiles in Reconstituted
Animals.
 
To characterize the intrahepatic inflammatory
response, total hepatic RNA from the nontumorous livers
from six representative animals of each group (Fig. 3, lanes
 
1
 
–
 
18
 
) was analyzed for the presence of T cell, macrophage,
and cytokine transcripts using an RNase protection assay
we have described previously (28, 30). The results were
compared with total hepatic RNA from a similar group of
transgenic mice killed at the peak of a CTL-induced acute
hepatitis (Fig. 3, lanes 
 
19
 
–
 
21
 
) 3 d after adoptive transfer of
10
 
7
 
 HBsAg-specific CTLs from a clone (6C2) we have
shown previously to cause fulminant hepatitis in these ani-
mals (26), at which time their sALT activity was 3,213 
 
6
 
303 (mean 
 
6
 
 SEM) U/liter, i.e., 10–20 times higher than
group 1 and 2 animals, respectively. As expected, the high-
est level of T cell, macrophage, and cytokine mRNA ex-
pression was observed in the acute hepatitis specimens
(lanes 
 
19
 
–
 
21
 
), followed, in order, by group 1 (lanes 
 
1
 
–
 
6
 
),
then group 2 (lanes 
 
7
 
–
 
12
 
), and finally group 3 (lanes 
 
13
 
–
 
18
 
) which represents the baseline for this analysis. It is
noteworthy that IFN-
 
g
 
 mRNA was detectable only in the
acutely inflamed livers, suggesting that the quality as well as
the magnitude of the inflammatory infiltrate is different in
these acute and chronic hepatitis models. These results
demonstrate that the T cell markers and TNF-
 
a
 
 mRNA
content were greater in group 1 than group 2 at the time of
autopsy. Considering the different sALT profiles in these
two groups throughout the experiment (Fig. 1), these re-
 
Table 1.
 
Biochemical, Histological, and Immunological Features of HBV Transgenic Mice as a Consequence of Chronic
Immune-mediated Hepatitis
 
Group Mouse ID
Age
at killing
Final
HBsAg
Final
 
a
 
HBs
Initial
sALT
Peak
sALT
Final
sALT
Liver
tumor
No. of
tumors
Largest
tumor
Tumor
histology
CTL
(% lysis)
 
mo mm
 
1 283 18
 
21
 
12 2100 308
 
1
 
4–5 10 HCC 46
284 18
 
21
 
60 3090 780
 
1
 
3 3 Adenoma 35
285 18 ND
 
1 60 5130 360 1 4 12 HCC ND
180 19 21 48 3300 188 1. 25 20 HCC 81
183 19 21 66 2850 392 1 8 15 HCC 38
243 19 21 18 6210 232 1. 25 20 HCC 59
251 19 ND 1 30 4920 136 1 1 12 HCC ND
254 19 21 60 4410 220 1 5 15 HCC 69
177 20 21 60 2580 80 1 6 6 HCC 60
22 7 1 7 N D 2 48 84 84 2 00 N D
22 18 ND 2 30 72 72 2 00 N D
355 21 12 48 348 348 1 1 10 Adenoma 0
359 21 12 30 184 184 2 00 1
387 21 ND 2 24 120 120 2 00 N D
388 21 12 24 116 116 2 00 1 7
82 1 12 24 88 88 1 1 9 HCC 0
396 21 12 30 108 84 2 00 6
34 21 12 18 332 332 2 00 0
3 308 16 12 42 180 180 2 00 2
290 19 22 54 54 32 2 00 2
315 21 12 24 40 40 2 00 N D
303 21 12 42 104 104 2 00 N D
351 21 12 72 80 80 2 00 N D
352 21 12 36 48 48 2 00 N D
342 21 12 72 72 68 2 00 N D
356 21 12 36 84 84 2 00 1
357 21 12 48 96 96 2 00 0
358 21 12 36 52 52 2 00 0346 Immune Response, Chronic Hepatitis, and Hepatocellular Carcinoma
sults suggest that the inflammatory liver disease began
much earlier and was more severe in group 1 than in group
2, probably explaining the higher incidence of HCC in
group 1 animals.
HBsAg-specific CTL Responses in Reconstituted Animals.
To assess the possible contribution of CTL response to the
pathogenesis of the liver disease in all three groups of recip-
ients, spleens harvested at the end of the experiment were
examined for HBsAg-specific cytotoxic activity. As seen
in Fig. 4 A, all of the group 1 mice (left) displayed strong
HBsAg-specific CTL responses. In contrast, only one of
the group 2 control mice (middle) showed a weak CTL re-
sponse which was not detectable in any of the group 3 con-
trols (right). The CTL activity of group 1 spleen cells was
inhibited by an mAb specific for CD8 but not CD4 (Fig. 4
B, left). The antigenic fine specificity of the group 1 CTL
response was examined using P815 target cells pulsed with
a previously defined Ld-restricted immunodominant CTL
epitope located between residues 28 and 39 of HBsAg
(HBsAg 28–39; reference 29). As shown in Fig. 4 B (mid-
dle), CTLs from all but one of the group 1 animals were
specific for that epitope, although their cytotoxic activity
was generally weaker than that of HBs-vac–primed non-
transgenic mouse splenocytes (Fig. 4 B, right). Splenocytes
from the single group 1 mouse whose CTLs did not recog-
nize peptide HBsAg 28–39 responded to a subdominant
Dd-restricted CTL epitope located between amino acids
281 and 289 in HBsAg (not shown).
Discussion
Hepatocarcinogenesis during chronic HBV infection is a
complex multifactorial process in which liver cell turnover
plays an important role. In support of this notion, we have
reported that hepatocellular injury triggered by overexpres-
sion of the HBV large envelope protein triggers hepatocel-
lular regeneration, oxidative DNA damage, clonal expan-
sion, and HCC (18–23). Although the large envelope
protein is probably not expressed at toxic levels during nat-
ural HBV infection, the same downstream events (i.e., re-
generation, DNA damage, etc.) could be induced in the
chronically infected liver by CTL-mediated destruction of
infected hepatocytes.
To test this hypothesis, we developed a model of chronic
immune-mediated liver disease using transgenic mice that
express nontoxic concentrations of the large, middle, and
small envelope proteins in the hepatocyte. Similar to hu-
man chronic HBsAg carriers, these mice are immunologi-
cally tolerant to HBsAg and develop no evidence of liver
disease except ground glass hepatocytes during their life-
time. 3-mo-old male transgenic mice (group 1) were
thymectomized, lethally irradiated (900 rads), and reconsti-
tuted with bone marrow and spleen cells from syngeneic
nontransgenic donors that had been previously immunized
with HBsAg-vac and displayed HBsAg-specific CTLs and
anti-HBs Abs. Similarly treated transgenic control animals
(group 2) were reconstituted with bone marrow and spleen
cells from immunologically tolerant transgenic donors. All
results were compared with unmanipulated age- and sex-
matched transgenic mice (group 3).
All of the group 1 mice developed acute hepatitis and
cleared HBsAg from their serum. Subsequently, all of these
mice developed chronic hepatitis, and their livers contained
increased numbers of CD41 and CD81 T cells. All nine of
the animals in this group developed one or several large
liver tumors, all but one of which were histologically con-
Figure 3. Intrahepatic T cell and cyto-
kine profiles in HBV transgenic mice. Total
RNA was extracted from nontumorous
liver tissue of representative mice from each
group 17 mo after adoptive transfer (groups
1 and 2) and from unmanipulated age-
matched controls (group 3), and subjected
to RNase protection analysis to monitor the
expression of CD3g, CD4, CD8a, F480,
and a panel of inflammatory cytokines.
Lanes  19–21 contain total liver RNA from
three HBV transgenic mice that were in-
jected with an HBsAg-specific CTL clone
which induced a severe transient acute hep-
atitis in transgenic recipients (references 26
and 28). The ribosomal protein light 32
(L32) RNA was used to normalize the
amount of RNA loaded in each lane.347 Nakamoto et al.
sistent with HCC. Importantly, an HBsAg-specific CTL
response was detectable in the spleen of these animals.
These results suggest that the mice developed a chronic in-
flammatory liver disease due to a relatively inefficient intra-
hepatic immune response that killed some of the HBsAg1
hepatocytes without downregulating HBV gene expres-
sion. This contrasts with the profound downregulation of
HBV gene expression that occurs during CTL-induced
acute hepatitis in these mice and related lineages due to the
antiviral effects of IFN-g and TNF-a produced by the an-
tigen-activated CTLs (28, 30, 31). Indeed, HBsAg1 hepa-
tocytes were present in the livers of these animals at the
time of autopsy, representing a continuing supply of target
cells for T cell recognition and continuing liver cell injury.
Interestingly, however, the number of HBsAg1 hepato-
cytes was lower in group 1 animals than in the other two
groups, possibly reflecting partial downregulation by intra-
hepatic cytokines, particularly TNF-a, which was more
strongly induced in group 1 than in the other animals (Fig. 4).
In contrast to group 1, the group 2 mice did not clear
HBsAg from their serum or develop acute hepatitis, pre-
sumably because the adoptively transferred transgenic spleen
cells did not contain HBsAg-specific B cells or CTLs. None-
theless, these animals developed chronic hepatitis very slowly
as they aged, and the disease was less severe than that ob-
served in group 1 animals. In keeping with these observa-
tions, HBsAg-specific CTLs were not detectable in their
spleens at autopsy, and their livers contained fewer acti-
vated T cells than group 1 animals. Accordingly, only a sin-
gle liver tumor was detectable in only two of the nine
(22%) animals in this group, and only one of them was his-
tologically consistent with HCC. As expected, all 13 of the
control animals in group 3 displayed histologically normal
livers, except for ground glass hepatocytes and minimal in-
flammatory infiltrates, for their lifetimes, and none pro-
duced CTLs or developed HCC.
Although the primary immunological mechanism re-
sponsible for chronic hepatitis in group 1 mice is not known
at this time, in view of our previous experiments demon-
strating that adoptively transferred HBsAg-specific CD41
and CD81 T cell clones cause acute hepatitis in this lineage
(25, 26, 32), it is likely that one or both T cell subsets are
involved. Whereas the initial episode of acute hepatitis was
clearly related to the spleen cell transfer, the chronic hepa-
titis could be due to primed splenic memory cells or to na-
ive T cells emerging from the nontransgenic bone marrow
in these animals. This interesting distinction will be pur-
sued in future experiments.
We do not understand the basis for the elevated transam-
inases and inflammatory liver disease appearing late in the
course of this experiment in some of the group 2 animals.
We suspect that this reflects a slow-onset, radiation-induced
hepatitis. However, it is also possible that HBs-specific T
cell precursors could have emerged from the marrow, es-
caped central deletion because of the absence of the thymus,
and expanded slowly in the periphery without any patho-
Figure 4. (A) In vitro cytotoxic activity
of splenocytes from group 1, 2, and 3 mice
at the time of autopsy. Splenocytes from in-
dividual mice were stimulated in vitro every
7 d with irradiated P815 cells that stably ex-
press the HBV envelope proteins
(P815preS1 cells). 2 wk later, the cytolytic
activity of the resultant T cell lines was as-
sessed in a standard 4-h cytotoxicity assay
with  51Cr-labeled P815 cells and P815
transfectants that express the HBV small en-
velope polypeptide (P815-S) at the E/T ra-
tios shown. Each line represents the cy-
tolytic activity detectable in an individual
mouse. (B) Characteristics of in vitro cyto-
toxic activity of splenocytes from group 1
mice and HBs-vac–primed nontransgenic
mice.  Left, The influence of anti-CD4 and
anti-CD8 Abs on the HBsAg-specific cy-
tolytic activity of group 1 spleen cells that
had been stimulated for an additional 1 wk
and tested for cytolytic activity against P815
and P815-S target cells at an E/T ratio of
50:1 in the presence of a rat mAb specific
for mouse CD4 or CD8 or a control Ab.
Columns with the same pattern indicate cy-
totoxic activity of splenocytes from the
same mouse. Middle, Cytolytic activity of
group 1 spleen cells against P815 cells that
had been pulsed either with the indicated
concentrations of a synthetic peptide representing residues 28–39 of HBsAg or with media at an E/T ratio of 50:1. Right, Cytolytic activity of similarly
stimulated splenocytes from HBs-vac–primed nontransgenic B10D2 (H-2d) mice identical to those used as group 1 donors. Middle and right, Each line
represents the cytolytic activity detectable in an individual mouse.348 Immune Response, Chronic Hepatitis, and Hepatocellular Carcinoma
logical consequences until they reached sufficient numbers
after several months in some of the mice to cause hepatitis.
The absence of HBs-specific CTLs in the spleens of these
mice suggests that CD41 T cells may have contributed to
the liver disease in these animals, as we suggested above for
the group 1 animals.
The pathogenetic importance of immune-mediated
hepatocellular injury in hepatocarcinogenesis in this study
is strengthened by the fact that HCC occurs in the context
of necrosis, inflammation, and regeneration (cirrhosis) in
several human liver diseases other than HBV, including
chronic hepatitis C (for a review, see reference 33), alco-
holism (34), hemochromatosis (35), glycogen storage dis-
ease (36), a1-antitrypsin deficiency (37, 38), and primary
biliary cirrhosis (39). Therefore, irrespective of etiology or
pathogenesis, it would appear that chronic liver cell injury
is a premalignant condition that initiates a cascade of events
characterized by increased rates of cellular DNA synthesis
and production of endogenous mutagens coupled with
compromised cellular detoxification and repair functions. If
these processes are sustained for a sufficiently long period of
time, they would be expected to cause the multiple genetic
and chromosomal changes necessary to trigger the develop-
ment of HCC. This notion is supported by the close corre-
lation between chronic inflammation and carcinogenesis
both in animal models of wounding and inflammation that
lead to skin cancer (40–42), and in humans, where contin-
uous oral irritation leads to oral cancer (43), chronic in-
flammatory bowel disease predisposes to bowel cancer (44–
47), chronic cystitis precedes bladder cancer (48–52), and
reflux esophagitis leads to esophageal cancer (53, 54).
Although these associations strongly suggest that chronic
necroinflammation may be procarcinogenic in regenerative
tissues, they do not constitute proof of this concept. However,
these results provide definitive evidence that HBV-specific
chronic immune-mediated liver cell injury is sufficient to
initiate and sustain the process of hepatocarcinogenesis in
this model. Furthermore, they demonstrate that the immune
response is procarcinogenic despite the absence of cofactors
such as viral integration, X gene expression, or genotoxic
agents, which have been proposed to contribute to the de-
velopment of HCC in humans. Since the immunological,
virological, and histological features of this model closely
resemble human chronic hepatitis, the results suggest that
an ineffective immune response is the principal oncogenic
factor during chronic HBV infection in humans. It is ironic
that the same T cell response that can eradicate HBV from
the liver when it is strong can be procarcinogenic by trig-
gering a chronic necroinflammatory liver disease when it is
unable to completely terminate the infection. If this is cor-
rect, therapeutic enhancement of the T cell response to
HBV in chronically infected patients should prevent HCC.
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